QN 247CE
Alternative Names: ALAN-CE; Aptamer linked anti-nucleolin - contrast enhancement; QN-247CELatest Information Update: 28 Dec 2023
At a glance
- Originator University of Louisville
- Class Diagnostic agents; Imaging agents
- Mechanism of Action Diagnostic imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for preclinical development in Solid-tumours(Diagnosis) in USA (Parenteral)
- 31 Dec 2021 Preclinical development in Solid-tumours (Diagnosis) ongoing in USA (Parenteral) (Qualigen Therapeutics pipeline, December 2021)
- 15 Dec 2020 Qualigen Therapeutics has patent protection for the ALAN technology in USA